| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:54 UTC |
|---|
| HMDB ID | HMDB0015204 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Mequitazine |
|---|
| Description | Mequitazine, also known as kitazemin, belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. Mequitazine is a drug which is used for the treatment of hay fever, urticaria (hives) and allergic rhinitis. In humans, mequitazine is involved in the mequitazine h1-antihistamine action pathway. Mequitazine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Mequitazine. |
|---|
| Structure | C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12 InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2 |
|---|
| Synonyms | | Value | Source |
|---|
| Kitazemin | Kegg | | Mequitazine hydrochloride | MeSH, HMDB | | 3-Methylquinuclidinyl-10-phenothiazine | MeSH, HMDB | | Mircol | MeSH, HMDB | | Mequitazine tartrate, (R-(r*,r*))-isomer | MeSH, HMDB | | Primalan | MeSH, HMDB | | Quitadrill | MeSH, HMDB |
|
|---|
| Chemical Formula | C20H22N2S |
|---|
| Average Molecular Weight | 322.467 |
|---|
| Monoisotopic Molecular Weight | 322.150369404 |
|---|
| IUPAC Name | 10-{1-azabicyclo[2.2.2]octan-3-ylmethyl}-10H-phenothiazine |
|---|
| Traditional Name | mequitazine |
|---|
| CAS Registry Number | 29216-28-2 |
|---|
| SMILES | C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12 |
|---|
| InChI Identifier | InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2 |
|---|
| InChI Key | HOKDBMAJZXIPGC-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzothiazines |
|---|
| Sub Class | Phenothiazines |
|---|
| Direct Parent | Phenothiazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenothiazine
- Alkyldiarylamine
- Diarylthioether
- Aryl thioether
- Quinuclidine
- Tertiary aliphatic/aromatic amine
- Piperidine
- Para-thiazine
- Benzenoid
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Thioether
- Organopnictogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 130.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.004 g/L | Not Available | | LogP | 4.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.9 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.0589 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.02 minutes | 32390414 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Mequitazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-03dj-1792000000-f3d460bef0cf903cf810 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Mequitazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Mequitazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Mequitazine LC-ESI-qTof , Positive-QTOF | splash10-0229-3984000000-3ce274e900b70e58cb37 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Mequitazine , positive-QTOF | splash10-0229-3984000000-3ce274e900b70e58cb37 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 10V, Positive-QTOF | splash10-00di-0409000000-67b79e76ee71f682ee1c | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 20V, Positive-QTOF | splash10-00di-0902000000-e17e677434bd389f6045 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 40V, Positive-QTOF | splash10-00di-0900000000-fa7f5c70f1d14d13235b | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 10V, Negative-QTOF | splash10-00di-0109000000-bbd40c8f9af776ed7e80 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 20V, Negative-QTOF | splash10-03k9-0494000000-6d797cc31cfccb88916e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 40V, Negative-QTOF | splash10-0002-0900000000-c2249f8b238ba5566b1f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 10V, Positive-QTOF | splash10-00di-0009000000-03444c42dcebceb6672f | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 20V, Positive-QTOF | splash10-00di-0109000000-f3f253fc57f0d8d77656 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 40V, Positive-QTOF | splash10-00di-0910000000-de1b7c931a543c5a98b8 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 10V, Negative-QTOF | splash10-00di-0009000000-22df2d00d88cf944e0dc | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 20V, Negative-QTOF | splash10-00di-0009000000-22df2d00d88cf944e0dc | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Mequitazine 40V, Negative-QTOF | splash10-0002-0910000000-d23c7cca4442260dfafe | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | |
|---|
| Biospecimen Locations | |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01071 | | details | | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB01071 | | details |
|
|---|
| Abnormal Concentrations |
|---|
| Not Available |
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | None |
|---|
| Associated OMIM IDs | None |
|---|
| External Links |
|---|
| DrugBank ID | DB01071 |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 3926 |
|---|
| KEGG Compound ID | C12755 |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Mequitazine |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | Not Available |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | Not Available |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | Not Available |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| Material Safety Data Sheet (MSDS) | Not Available |
|---|
| General References | - Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, Shimizu T, Kamataki T: Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42. [PubMed:9454781 ]
- Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J: Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis. Allergy. 1997 Apr;52(4):451-4. [PubMed:9188930 ]
- Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG: A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy. 2004 Feb;34(2):250-8. [PubMed:14987305 ]
- Ramirez Chanona N, del Rio Navarro BE, Perez Martin J: [Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience]. Rev Alerg Mex. 2005 Nov-Dec;52(6):221-5. [PubMed:16568706 ]
|
|---|